• Explore /
  • Poster
  • / Initial results from a phase II study of increased-dose abiraterone acetate in patients with castration resistant prostate cancer (CRPC).

Initial results from a phase II study of increased-dose abiraterone acetate in patients with castration resistant prostate cancer (CRPC).

Abstract Poster

Authors

null

Terence W. Friedlander

University of California, San Francisco, San Francisco, CA

Terence W. Friedlander , Julie Nicole Graff , Li Zhang , Rosa Paz , Gayatri Premasekharan , Archana Dilip , Andrew Caleb Hsieh , Rahul Raj Aggarwal , Won Kim , Amy M. Lin , Lawrence Fong , Eric Jay Small , Pamela Paris , Charles J. Ryan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT01637402

Citation

J Clin Oncol 33, 2015 (suppl 7; abstr 188)

DOI

10.1200/jco.2015.33.7_suppl.188

Abstract #

188

Poster Bd #

H24

Abstract Disclosures

Similar Posters

First Author: Mary-Ellen Taplin

First Author: Guillaume Grisay

First Author: Alicia K. Morgans

First Author: Benjamin H Lowentritt